Cargando…

1156. Real-World Effectiveness of Recombinant Zoster Vaccine in Chinese Adults Aged ≥50 Years in the US

BACKGROUND: Following the May 2019 approval of recombinant zoster vaccine (RZV) in China, there was a need for real-world information on the vaccine effectiveness (VE) of RZV in a Chinese population. We conducted a retrospective cohort study at Kaiser Permanente Southern California (KPSC) to estimat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Florea, Ana, Sy, Lina S, Qian, Lei, Ackerson, Bradley, Luo, Yi, Wu, Jun, Cheng, Yanjun, Ku, Jennifer H, Vega Daily, Leticia I, Takhar, Harpreet, Song, Jeannie, Chmielewski-Yee, Elizabeth, Spence, O M areen, Seifert, Harry, Oraichi, Driss, Tseng, Hung Fu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676851/ http://dx.doi.org/10.1093/ofid/ofad500.996

Ejemplares similares

Herpes Zoster Following Recombinant Zoster Vaccine With or Without Concomitant Vaccination
por: Bruxvoort, Katia J, et al.
Publicado: (2022)

917. Development and Validation of an Automated Natural Language Processing Method for Identifying Postherpetic Neuralgia from Electronic Health Records
por: Zheng, Chengyi, et al.
Publicado: (2023)

19. Completion of Two-Dose Recombinant Zoster Vaccine Series in Adults 50 Years and Older
por: Tseng, Hung-Fu, et al.
Publicado: (2020)

2300. Incidence, Complications, and Recurrence of Herpes Zoster in Unvaccinated Adults ≥50 Years of Age
por: Ackerson, Bradley, et al.
Publicado: (2019)

The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults ≥50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence
por: Tseng, Hung Fu, et al.
Publicado: (2020)

1156. Observation of Stethoscope Sanitation Practices in an Emergency Department Setting
por: Vasudevan, Rajiv, et al.
Publicado: (2018)

1156. Pneumococcal Colonization in Children with Persistent Asthma and without Asthma
por: Olarte, Liset, et al.
Publicado: (2021)

Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study
por: Bruxvoort, Katia J., et al.
Publicado: (2021)

Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants
por: Tseng, Hung Fu, et al.
Publicado: (2022)

Bipolar Thermofusion BiClamp 150 in Thyroidectomy: A Review of 1156 Operations
por: Pniak, Tomáš, et al.
Publicado: (2014)

1156. Clinical and epidemiological features and outcomes of Blastomycosis in a tertiary hospital in Kentucky
por: Cari, Evelyn Villacorta, et al.
Publicado: (2020)

Text-Based Identification of Herpes Zoster Ophthalmicus With Ocular Involvement in the Electronic Health Record: A Population-Based Study
por: Zheng, Chengyi, et al.
Publicado: (2021)

Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults
por: Bruxvoort, Katia J, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Corrigendum: Kato M, Kawakita A (2023) Diversity and larval leaf-mining habits of Japanese jewel beetles of the tribe Tracheini (Coleoptera, Buprestidae). ZooKeys 1156: 133–158. doi: 10.3897/zookeys.1156.97768
por: Kato, Makoto, et al.
Publicado: (2023)

Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model
por: Patterson, Brandon J, et al.
Publicado: (2020)

mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence
por: Parikh, Raunak, et al.
Publicado: (2023)

Predominantly myalgic phenotype caused by the c.3466G>A p.A1156T mutation in SCN4A gene
por: Palmio, Johanna, et al.
Publicado: (2017)

Distribution of SARS-CoV-2 Variants in a Large Integrated Health Care System — California, March–July 2021
por: Malden, Deborah E., et al.
Publicado: (2021)

1156. Running on Empty: Enlisting Transportation Services in Quality Improvement Initiatives as a Safeguard Against Catheter-Associated Urinary Tract Infections
por: Lobo, Dale, et al.
Publicado: (2019)

1156: A COMPARISON BETWEEN REAL WORLD WEIGHT LOSS OUTCOMES WITH ANTI-OBESITY MEDICATIONS BEFORE AND DURING COVID-19 PANDEMIC
por: Rosa, Alan De la, et al.
Publicado: (2022)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

2284. Ten-Year Effectiveness of Live Virus Herpes Zoster Vaccine
por: Tseng, Hung Fu, et al.
Publicado: (2018)

784. Real-world effectiveness of the mRNA-12733-dose primary series against COVID-19 in an immunocompromised population Interim results from a prospective observational cohort study
por: Ku, Jennifer H, et al.
Publicado: (2022)

Burden of herpes zoster: the direct and comorbidity costs of herpes zoster events in hospitalized patients over 50 years in France
por: Blein, Cecile, et al.
Publicado: (2015)

Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study
por: Florea, Ana, et al.
Publicado: (2022)

WCN23-1156 INCIDENCE RATE OF COVID-19 HEMODIALYSIS UNIT ADMISSION AMONG CONGOLESE PATIENTS: EXPERIENCE DURING THE FIRST 4 WAVES OF THE PANDEMIC
por: Nlandu Mayamba, Y., et al.
Publicado: (2023)

Risk of Herpes Zoster in Relation to Body Mass Index Among Residents Aged ≥50 Years: The Shozu Herpes Zoster Study
por: Kawahira, Kazuhiro, et al.
Publicado: (2022)

Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults
por: Florea, Ana, et al.
Publicado: (2022)

Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study
por: Ku, Jennifer H., et al.
Publicado: (2023)

Epidemiology of herpes zoster among adults aged 50 and above in Guangdong, China
por: Zhu, Qi, et al.
Publicado: (2015)

Multiple Genes Related to Muscle Identified through a Joint Analysis of a Two-stage Genome-wide Association Study for Racing Performance of 1,156 Thoroughbreds
por: Shin, Dong-Hyun, et al.
Publicado: (2015)

Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study
por: Ku, Jennifer H., et al.
Publicado: (2023)

Impact of herpes zoster and postherpetic neuralgia on the quality of life of Germans aged 50 or above
por: Curran, Desmond, et al.
Publicado: (2018)

2656. Eliciting Preferences for Zoster Vaccination in US Adults Aged 50 Years and Older
por: Patterson, Brandon J, et al.
Publicado: (2019)

115. Post-licensure Safety Study of New-onset Immune-mediated Diseases, Herpes Zoster, and Anaphylaxis in Adult Recipients of HepB-CPG Vaccine Versus HepB-alum Vaccine
por: Ackerson, Bradley, et al.
Publicado: (2022)

8. The Adjuvanted Recombinant Zoster Vaccine (RZV) Confers Long-term Protection Against Herpes Zoster: Interim Results of an Extension Study (ZOSTER-049) of Two Clinical Trials (ZOE-50 and ZOE-70)
por: Boutry, Céline, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_cvgt1oas1gjs9j4b1g2otk3es8